5879-98-1Relevant articles and documents
Total synthesis of lasofoxifene and nafoxidine
Umareddy, Pailla,Arava, Veera Reddy
supporting information, p. 309 - 313 (2016/04/05)
An intramolecular reductive coupling process of diketone with low-valent titanium species to form a dihydronapthalene skeleton was an important step in the synthesis of nafoxidine (1) and lasofoxifene (2). Diketone 6 was prepared in a convenient, three-st
Pharmaceutical composition having uniform drug distribution and potency
-
, (2008/06/13)
Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compositions are disclosed.
Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
-
, (2008/06/13)
A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions.
Estrogen agonists/antagonists
-
, (2008/06/13)
Compounds of formula A inhibit bone resorption and bone turnover, prevent bone loss, preserve bone strength and decrease serum cholesterol without causing prostate hypertrophy in male mammals: and E and B are selected from CH and N. R4 is H, OH, F or Cl.
Estrogen agonists/antagonists
-
, (2008/06/13)
Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
-
, (2008/06/13)
Compounds of this formula STR1 are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.